PerkinElmer splits in two

Today's Big News

Mar 14, 2023

The delisting dilemma: Why do so many biotechs face being kicked off the Nasdaq?


Novo Nordisk follows Eli Lilly's lead, slashing insulin prices in the US


PerkinElmer completes $2.45B spinoff to create new diagnostics, life sciences company


With billions of dollars on the line, Bayer survey finds flaws in kidney disease communication, diagnosis


Insulet tapped to replace SVB on S&P 500 index after bank collapse

 

Featured

The delisting dilemma: Why do so many biotechs face being kicked off the Nasdaq?

The latest fear stalking biotech boardrooms isn’t a trial fail or an underwhelming funding haul, it’s the postman delivering a letter from Nasdaq warning that the company’s stock faces being delisted from the stock exchange.
 

Top Stories

Novo Nordisk follows Eli Lilly's lead, slashing insulin prices in the US

Two weeks after Eli Lilly answered the call to slash prices of its insulin products in the U.S., Novo Nordisk has followed suit. On Tuesday, the Danish company said it would reduce the list price of its NovoLog insulin by 75% and slice the cost of Novolin and Levemir by 65%.

PerkinElmer completes $2.45B spinoff to create new diagnostics, life sciences company

Right on schedule, PerkinElmer has completed the split it announced last August, selling off its applied science, food and enterprise services businesses to private equity firm New Mountain Capital and combining the remaining life sciences and diagnostics businesses into a new, standalone company.

With billions of dollars on the line, Bayer survey finds flaws in kidney disease communication, diagnosis

Chronic kidney disease (CKD) should be among the top health concerns of diabetes patients. Yet, while around 1 in 3 adults with diabetes has CKD, a Bayer survey of healthcare professionals shows that people are often unprepared for their diagnosis and that communication needs to improve.

Insulet tapped to replace SVB on S&P 500 index after bank collapse

Silicon Valley Bank's parent company SVB Financial Group is no longer eligible for inclusion on the S&P 500 and will therefore be removed from the index before the markets open on Wednesday—at which point Insulet will step in to take its place.

Chasing Pfizer, GSK's 5-in-1 meningococcal vaccine delivers phase 3 trial win

GSK's combination MenABCWY vaccine has been in the works for years, but always running slightly behind Pfizer's rival shot. Now, in a phase 3 trial, the GSK shot proved itself against GSK's approved meningitis vaccines Bexsero and Menveo.

Synaffix, MacroGenics crack open ADC pact, tacking on $2.2B, 4 more programs

Synaffix and MacroGenics are expanding their existing ADC-focused collaboration, upping the deal by $2.2 billion and putting four more targets on the table. The move comes as interest in ADCs grows at a rapid pace.

European AIDS advocacy group keeps Gilead in the crosshairs as it lambasts the pharma for its ‘greedy tactics’

Following in the footsteps of the AIDS Healthcare Foundation (AHF) group in the U.S., its European base is upping the pressure on Gilead’s AIDS/HIV and hepatitis C drug policies on the continent.

Heart tissue on a chip is headed back up to the International Space Station

Projects by teams from Stanford University and Johns Hopkins University will be part of the payload March 14 on SpaceX CRX-27, a resupply mission to the International Space Station. The researchers hope to leverage aging effects of microgravity on heart muscle cells to ultimately help identify new treatments for cardiovascular disease.

Philips finds new head of recall-laden connected care segment in Pear Therapeutics exec

As Philips prepares to enter the third year of its recall of 5.5 million CPAP and BiPAP machines and other respiratory devices, the Dutch devicemaker has appointed a new leader for its beleaguered connected care division.
 
Fierce podcasts

Don't miss an episode

'The Top Line': Why pharma needs to ramp up its use of AI and machine learning, plus this week's headlines

This week on "The Top Line," we take on AI and machine learning in the pharma and healthcare universe. The expectation is that these tools will speed up innovation and open up new markets, helping the sector stay ahead of the curve. Plus, this week's headlines.
 

Resources

Whitepaper

Plan for scalable process liquid and buffer preparation

Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation.
Executive Summary

Optimizing drug discovery in a fast-moving market

Read about the latest survey results from over 200 biopharma executives and the changing approaches to building biologic drug development pipelines.
Whitepaper

Answering your specific questions about mRNA/saRNA manufacturing

Have you had your questions about mRNA/saRNA manufacturing unanswered during a webinar; have no fear, we have you covered here.
Whitepaper

Proven Pharmaceutical Go-To-Market Model

Download Herspiegel Consulting’s Go-To-Market Model, based on 100+ launches, to learn the critical components, and timelines for commercial success.

Research

Strategizing for Clinical Trial Diversity

Like many top 10 and global pharma companies, an H1 client needed to diversify both its patient outreach and site investigator profiles for upcoming trials.
Whitepaper

The Power of Small & Safety: Nanoplasmid™️ Vector Platform

Discover the Power of Small with NanoplasmidTM – the next-generation plasmid for manufacturing today’s cell and gene therapies.

Whitepaper

Leveraging Archetypes for Effective Launch Strategy

Learn more about critical success factors for your next launch based on the experience of 100+ pharma product launches.
Whitepaper

Intranasal Drug Product Development: Formulation to Manufacturing

What are key considerations for intranasal delivery in the treatment of acute and chronic conditions?
Whitepaper

Running Decentralized Trials at Scale

Explore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment.
Research

Step-wise strategy to address process characterization and late phase development

Learn more on Catalent’s step-wise approach for the definition and execution of Process Characterization for the production of a monoclonal antibody for late phase process characterization and development.

Case Study

A Strategy to Standardize Process Characterization & Late Phase Development

Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments.

Whitepaper

Designing an Optimal APAC Clinical Supply Chain

Discover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific.
Whitepaper

Key Clinical Supply Issues Sponsors Should Consider with their CRO

As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs.

Research

A Strategy to Standardize Process Characterization & Late Phase Development

Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments.

Whitepaper

Specialized Expertise for Management of Clinical Supply Budgets

For sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management.
Whitepaper

Clinical Supply Solutions for the Asia-Pacific Region

Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region.
Whitepaper

Roles and Responsibilities of Specialized Clinical Supply Experts

How can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis.
Whitepaper

Questions You Need to Ask Your CRO About Clinical Supply

Planning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial.
Whitepaper

Supply Services to Support Clinical Trials in Japan & Beyond

Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world.
 

Industry Events

 

Upcoming Fierce Events

14-15
Mar
San Francisco, CA
20-22
Mar
West Palm Beach, FL
3-4
Apr
San Diego, CA
1-3
May
May 1-3, 2023 | Jersey City, NJ
23
May
Free Virtual Event

View all events